Historique
Rapport
ADB-CHMINACA. Report on the risk assessment of N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA) in the framework of the Council Decision on new psychoactive substances
Auteur(s) :
OEDT = EMCDDA
Article en page(s) :
83 p.
Domaine :
Drogues illicites / Illicit drugs
Langue(s) :
Anglais
Discipline :
PRO (Produits, mode d'action, méthode de dépistage / Substances, action mode, screening methods)
Organismes
OEDT
Thésaurus mots-clés
CANNABINOIDES
;
CONTROLE DES STUPEFIANTS
;
FACTEUR DE RISQUE
;
DROGUES DE SYNTHESE
;
PHARMACOLOGIE
;
TYPE D'USAGE
;
EFFET SECONDAIRE
;
TOXICITE
;
INTOXICATION
;
MORTALITE
;
SURVEILLANCE EPIDEMIOLOGIQUE
Thésaurus géographique
EUROPE
Note de contenu :
TABLE OF CONTENTS:
- Foreword
- EMCDDA actions on monitoring and responding to new drugs.
- Europol-EMCDDA Joint Report on ADB-CHMINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide) - a summary.
- Risk Assessment Report on a new psychoactive substance: N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA).
- Technical report on N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA).
- Participants of the risk assessment meeting, 7-8 November 2017.
- Foreword
- EMCDDA actions on monitoring and responding to new drugs.
- Europol-EMCDDA Joint Report on ADB-CHMINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide) - a summary.
- Risk Assessment Report on a new psychoactive substance: N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA).
- Technical report on N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA).
- Participants of the risk assessment meeting, 7-8 November 2017.
Résumé :
This publication presents the data and findings of the risk assessment on N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. On the basis of the Risk Assessment Report - and on the initiative of the European Commission - on 14 May 2018, the Council decided that ADB-CHMINACA should be subject to control measures across the Member States.
Autre(s) lien(s) :
http://www.emcdda.europa.eu/news/2018/3/council-implementing-decisions-control-adb-chminaca-cumyl-4cn-binaca_en
Exemplaires
| Disponibilité |
|---|
| aucun exemplaire |